Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease.

Commercial, paid medical screening like blood tests, whole body MRIs and DEXA scans, which can evaluate bone density and ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...

BURLINGTON, N.C. - Labcorp (NYSE:LH), a prominent healthcare diagnostics provider with a market capitalization of $23.5 billion, announced Thursday it will offer the Elecsys pTau181 test nationwide by ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...

Labcorp announced it will begin offering the Elecsys pTau181 blood test nationwide by early 2026, making available the only FDA-cleared blood test in the U.S. to aid in the initial assessment for ...

In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease. The test--called the Lumipulse ...